Predictors and Prognosis of Symptomatic Intracranial Hemorrhage in Acute Ischemic Stroke Patients Without Thrombolysis: Analysis of Data From the Chinese Acute Ischemic Stroke Treatment Outcome Registry

A simple scoring to predict symptomatic intracranial hemorrhage after stroke thrombolysis: the EGAN score

BACKGROUND

Symptomatic intracranial hemorrhage (sICH) after intravenous thrombolysis represents a critical and fatal complication observed in acute ischemic stroke (AIS) patients. This study aims to establish a simple scoring model to predict sICH.

METHODS

We retrospectively conducted a cohort study of eligible AIS patients treated with rt-PA at a tertiary comprehensive stroke center from January 2018 to December 2022. Backward stepwise multivariable logistic regression provided the final model. The point score was generated from β-coefficients. The area under the curve (AUC) of the receiver operating characteristics (ROC) and the Hosmer-Lemeshow goodness-of-fit test were used to assess the discrimination and calibration of the model. The conditional probabilities were derived based on the Bayes theorem.

RESULTS

Of the included patients, sICH occurred in 26 (3.97%) of the 655. The EGAN score consisted of an early infarct sign (10 points), baseline glucose ≥200 mg/dL (11 points), atrial fibrillation (AF) (13 points), and an NIH Stroke Scale (NIHSS) score ≥10 (12 points). With a cut-off point of 13, the EGAN score demonstrated good discrimination (0.7453 [95% CI: 0.649-0.841]), sensitivity (80.77%), and specificity (58.19%), respectively, for identifying sICH.

CONCLUSIONS

This easy-to-use scoring model, based on predictors quickly obtained in clinical practices, offers a simple approach to screening for post-thrombolysis sICH and can serve as an alternative option in hospitals with limited resources for thrombolysis therapy.

Prolonged Hospital Length of Stay Does Not Improve Functional Outcome in Acute Ischemic Stroke

INTRODUCTION

Ischemic stroke is the second leading cause of mortality and a major contributor to disability worldwide. Hospital length of stay (LOS) is a marker of medical efficiency for stroke care. There is limited information on this issue in China. This study aimed to identify predictors of prolonged LOS and to assess whether a prolonged LOS benefits functional outcomes in patients with acute ischemic stroke (AIS) in China.

METHODS

This secondary analysis of the Chinese Acute Ischemic Stroke Treatment Outcome Registry, a multicenter, prospective, hospital-based registry study, included patients diagnosed as AIS and admitted to a hospital within 3 days after AIS onset from May 2015 to October 2017. Participants were dichotomized as the normal LOS group (LOS ≤ 14 days) and the prolonged LOS group (LOS > 14 days). The outcomes were the proportions of poor outcome at 3 months and 12 months after stroke onset. Poor outcome was defined as a mRS score of 3-6.

RESULTS

This study included 8171 patients (median age 64.0 years; 5367 male, 2804 female); 2968 (36.3%) patients had a prolonged LOS. Multivariable analysis identified independent predictors of prolonged LOS, including medical insurance, history of diabetes mellitus, stroke severity, use of anticoagulant agents, in-hospital infection complications, hemorrhagic events, and hospital region. A prolonged LOS was associated with a higher risk of poor outcome at 3 and 12 months after stroke, with this finding upheld in a propensity score-matched cohort as well as subgroup analyses stratified by stroke severity and age.

CONCLUSION

In this study, approximately one-third of patients with AIS experienced a prolonged LOS over 14 days. Independent predictors of prolonged LOS included medical insurance, history of diabetes mellitus, stroke severity, use of anticoagulant agents, in-hospital infection complications, hemorrhagic events, and hospital region. Extending the LOS beyond 14 days did not enhance the prognosis for patients with AIS. As an observational study, our research provided the foundation for further interventional studies. Graphical abstract available for this article.

TRIAL REGISTRATION

ClinicalTrials.gov NCT02470624.

A telemedicine-enabled intravenous thrombolytic treatment pathway for patients with hyperacute non-arteritic central retinal artery occlusion

Purpose

To describe the visual acuity (VA) outcomes from a telemedicine-enabled pathway allowing for rapid diagnosis and administration of intravenous (IV) thrombolytic treatment for non-arteritic central retinal artery occlusion (naCRAO) within 4.5 hours (4.5 h) of visual loss.

Design

Retrospective observational case series.

Methods

Setting: A large managed healthcare consortium.Patient Population: Eighty-five patients with naCRAO and vision loss for less than 4.5 h presenting between 2021 and 2023. Thirty-five patients received IV thrombolytic therapy and 50 patients were closely observed.Intervention: A collaborative telemedicine-enabled pathway employing fundus photography was previously established by Ophthalmology, Emergency Medicine, and Stroke services to rapidly evaluate and manage patients presenting with acute painless monocular vision loss and allow for administration of IV tenecteplase (0.25 mg/kg) for eligible consenting patients diagnosed with naCRAO within 4.5 h. Retrospective chart review was conducted to collect data on demographics, vascular risk factors, clinical features, VA outcomes, and adverse events. Comparison was made between patients who received intravenous thrombolysis and those who were observed.Main Outcome Measures: Improvement in VA of at least 0.3 logarithm of the minimum angle of resolution (logMAR) and/or from 20/200 or worse to 20/100 or better.

Results

A greater percentage of patients in the treated group had VA improvement of ≥0.3 logMAR (54.3 % vs 28 %, p = .014), and a greater percentage of patients in the untreated group had VA worsening of ≥0.3 logMAR (30 % vs 5.7 %, p = .006). Twice the percentage of treated versus untreated patients had improved VA from 20/200 or worse to 20/100 or better, but this difference was not statistically significant (20 % vs 10 %, p = .192). There was a significantly shorter mean time to treatment for those patients who had VA improvement from 20/200 or worse to 20/100 or better compared to those who did not (118 versus 171 min, p = .031). Two patients experienced intracranial bleeding after IV thrombolysis.

Conclusions

The evaluation and treatment of hyperacute naCRAO is possible on a large scale via an integrated telemedicine-enabled approach utilizing fundus photography. The use of IV thrombolytic was associated with better VA outcomes compared to observation alone. Prospective randomized controlled trials are needed to confirm these findings and determine optimal management.

Integrating Neutrophil-To-Albumin Ratio and Triglycerides: A Novel Indicator for Predicting Spontaneous Hemorrhagic Transformation in Acute Ischemic Stroke Patients

BACKGROUND

Hemorrhagic transformation (HT) is a tragic complication of acute ischemic stroke (AIS), with spontaneous HT (sHT) occurring even without reperfusion therapies. Despite evidence suggesting that several inflammation biomarkers are closely related to HT, its utility in sHT risk stratification remains unclear. This study aimed to identify and integrate effective inflammatory biomarkers associated with sHT and to develop a novel nomogram model for the early detection of sHT.

METHODS

We conducted a retrospective observational cohort study of AIS patients receiving conventional medical treatment solely from March 2022 to March 2023, using a prospectively maintained database. All patients underwent CT follow-up within 7 days after admission, with sHT occurrence within this period as the outcome. Data on demographics, clinical information, laboratory results, and imaging were collected. The cohort was divided into training and validation sets (7:3). Least absolute shrinkage and selection operator (LASSO) regression selected inflammatory biomarkers for a novel index. Univariable and multivariable logistic regressions were conducted to identify independent sHT risk factors. Receiver operating characteristic (ROC) analysis determined optimal cut-off values for continuous factors. A nomogram was developed and validated internally and externally. Predictive accuracy was assessed using the area under the ROC curve (AUC) and calibration plots. Decision curve analysis (DCA) evaluated clinical usefulness.

RESULTS

Of 803 AIS patients, 325 were included in the final analysis. sHT was found in 9.5% (31 patients). Training (n = 228) and validation (n = 97) cohorts showed no significant demographic or clinical differences. LASSO regression integrated neutrophil-to-albumin ratio (NAR) and triglycerides (TGs) into a novel index-NATG. Independent sHT risk factors included baseline National Institute of Health Stroke Scale (NIHSS) (OR = 1.09, 95% CI (1.02, 1.16), p = 0.0095), NATG (OR = 1534.87, 95% CI (5.02, 469638.44), p = 0.0120), D-dimer (DD) (OR = 1.12, 95% CI (1.01, 1.25), p = 0.0249), and total cholesterol (TC) (OR = 1.01, 95% CI (1.00, 1.01), p = 0.0280), with their respective optimal cut-off values being 13, 0.059, 0.86, and 3.6. These factors were used to develop the nomogram in the training cohort, which achieved an AUC of 0.804 (95% CI, 0.643-0.918) in the training cohort and 0.713 (95% CI, 0.499-0.868) in the validation cohort, demonstrating consistent calibration. DCA confirmed the nomogram's clinical applicability in both cohorts.

CONCLUSIONS

A novel indicator combining NAR and TG is positively associated with sHT in AIS patients. The constructed nomogram, integrating this novel indicator with other risk factors, provides a valuable tool for identifying sHT risk, aiding in clinical decision-making.

Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?

Coagulation and fibrinolytic system disorders are conditions in which the blood's ability to clot is impaired, resulting in an increased risk of thrombosis or bleeding. Although these disorders are the expression of two opposing tendencies, they can often be associated with or be a consequence of each other, contributing to making the prognosis of acute cerebrovascular events more difficult. It is important to recognize those conditions that are characterized by dual alterations in the coagulation and fibrinolytic systems to reduce the prognostic impact of clinical conditions with difficult treatment and often unfortunate outcomes. Management of these individuals can be challenging, as clinicians must balance the need to prevent bleeding episodes with the potential risk of clot formation. Treatment decisions should be made on an individual basis, considering the specific bleeding disorder, its severity, and the patient's general medical condition. This review aims to deal with all those forms in which coagulation and fibrinolysis represent two sides of the same media in the correct management of patients with acute neurological syndrome. Precision medicine, personalized treatment, advanced anticoagulant strategies, and innovations in bleeding control represent future directions in the management of these complex pathologies in which stroke can be the evolution of two different acute events or be the first manifestation of an occult or unknown underlying pathology.

Early Hemorrhagic Transformation after Reperfusion Therapy in Patients with Acute Ischemic Stroke: Analysis of Risk Factors and Predictors

Background: The standard reperfusion therapy for acute ischemic stroke (AIS) is considered to be thrombolysis, but its application is limited by the high risk of hemorrhagic transformation (HT). This study aimed to analyze risk factors and predictors of early HT after reperfusion therapy (intravenous thrombolysis or mechanical thrombectomy). Material and methods: Patients with acute ischemic stroke who developed HT in the first 24 h after receiving rtPA thrombolysis or performing mechanical thrombectomy were retrospectively reviewed. They were divided into two groups, respectively, the early-HT group and the without-early-HT group based on cranial computed tomography performed at 24 h, regardless of the type of hemorrhagic transformation. Results: A total of 211 consecutive patients were enrolled in this study. Among these patients, 20.37% (n = 43; age: median 70.00 years; 51.2% males) had early HT. Multivariate analysis of independent risk factors associated with early HT found that male gender increased the risk by 2.7-fold, the presence of baseline high blood pressure by 2.4-fold, and high glycemic values by 1.2-fold. Higher values of NIHSS at 24 h increased the risk of hemorrhagic transformation by 1.18-fold, while higher values of ASPECTS at 24 h decreased the risk of hemorrhagic transformation by 0.6-fold. Conclusions: In our study, male gender, baseline high blood pressure, and high glycemic values, along with higher values of NIHSS were associated with the increased risk of early HT. Furthermore, the identification of early-HT predictors is critical in patients with AIS for the clinical outcome after reperfusion therapy. Predictive models to be used in the future to select more careful patients with a low risk of early HT need to be developed in order to minimize the impact of HT associated with reperfusion techniques.

Thrombolysis in central retinal artery occlusion: a retrospective observational study

BACKGROUND

There is no evidence-based therapy for non-arteritic central retinal artery occlusion (NA-CRAO). Intravenous thrombolysis (IVT) with alteplase in a time window < 4.5 h may lead to a favorable outcome. Purpose of this study was to investigate the feasibility, efficacy and safety of IVT in patients classified as functionally blind.

METHODS

We conducted a retrospective observational study of NA-CRAO-patients. All patients underwent an ophthalmological and neurological examination including cerebral magnetic resonance imaging (MRI) for assessment of additional stroke lesions. Patients were treated either conservatively or with IVT within 4.5 h. Visual acuity (VA) was evaluated in logMAR and a categorical analysis was performed.

RESULTS

Thirty-seven patients were included in the study, 21 patients in the conservative treatment group (CTG) and 16 patients in the IVT group. The median logMAR visual acuity at admission and discharge was similar in both groups. The medium symptom to treatment time in the IVT group was 158.0 min. 3 patients (19%) of the IVT group showed a favorable outcome, all CTG patients remained at the level of functional blindness. No serious adverse events were observed after IVT. MRI showed additional acute stroke in over one-third of the patients (n = 14).

CONCLUSIONS

Early intravenous thrombolysis therapy according to the current stroke protocol n a time window up to 4.5 h after the onset of symptoms was feasible and might be a potential treatment option for NA-CRAO. Patients with NA-CRAO are at very high risk of ischemic stroke and MRI should be done in all patients for optimized treatment and secondary stroke prevention. A prospective randomized study is required.

Prognostic significance of the clinical and radiological haemorrhagic transformation subtypes in acute ischaemic stroke: A systematic review and meta-analysis

BACKGROUND AND PURPOSE

The aim was to investigate the associations of haemorrhagic transformation (HT) and its clinical and radiological subtypes with functional outcome, mortality, early neurological deterioration (END) and neurological complications in patients with acute ischaemic stroke (AIS).

METHODS

A systematic review and meta-analysis of observational studies on the associations of overall HT, clinical HT subtypes (asymptomatic intracerebral haemorrhage [aICH] and symptomatic intracerebral haemorrhage [sICH]) or radiological HT subtypes (haemorrhagic infarction [HI-1 or HI-2] and parenchymal haemorrhage [PH-1 or PH-2]) with prognosis in patients with AIS was performed. PubMed, Web of Science and Embase were systematically searched. Random effects models were used to calculate pooled estimates.

RESULTS

Fifty-one studies with 100,510 patients were pooled in the meta-analysis. Overall HT was associated with worse functional outcome (odds ratio [OR] 2.12, 95% confidence interval [CI] 1.55-2.90), increased mortality (OR 1.87, 95% CI 1.52-2.30), END (OR 2.35, 95% CI 1.46-3.77), early-onset seizures (OR 2.58, 95% CI 1.63-4.10) and post-stroke epilepsy (OR 2.23, 95% CI 1.11-4.49). For clinical subtypes, sICH remained significantly associated with the aforementioned poor prognoses except post-stroke epilepsy, and aICH was associated with worse functional outcome but was unrelated to mortality. For radiological subtypes, PH (especially PH-2) was strongly associated with poor prognosis. HI-2 was associated with worse functional outcome, and HI-1 was associated with a lower risk of mortality and END.

CONCLUSIONS

Regardless of whether AIS patients undergo thrombolysis or thrombectomy, overall HT, sICH and PH (especially PH-2) are associated with a substantially increased risk of worse functional outcome, mortality, END or neurological complications. The presence of aICH is related to worse functional outcome but is independent of increased mortality. HI-2 impairs functional independence, and HI-1 does not cause neurological impairment.